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Abstract  
Background:  
The  importance  of  the  Notch  signaling  in  the  development  of  glomerular  diseases  has  been 
recently described. Therefore we analyzed in podocytes the expression and activity of ADAM10, 
one important component of the Notch signaling complex .  
Methods:  By  Western  blot,  immunofluorescence  and  immunohistochemistry  analysis  we 
characterized the expression of ADAM10 in human podocytes, human urine and human renal 
tissue. 
Results: 
We  present  evidence,  that  differentiated  human  podocytes  possessed  increased  amounts  of 
mature  ADAM10  and  released  elevated  levels  of  L1  adhesion  molecule,  one  well  known 
substrate of ADAM10. By using specific siRNA and metalloproteinase inhibitors we demonstrate 
that  ADAM10  is  involved  in  the  cleavage  of  L1  in  human  podocytes.  Injury  of  podocytes 
enhanced the ADAM10 mediated cleavage of L1. In addition, we detected ADAM10 in urinary 
podocytes from patients with kidney diseases and in tissue sections of normal human kidney. 
Finally, we found elevated levels of ADAM10 in urinary vesicles of patients with glomerular 
kidney diseases. 
Conclusions:   
The activity of ADAM10 in human podocytes may play an important role in the development of 
glomerular kidney diseases. 
       
Background 
The important role of podocytes in the development of many glomerular diseases are documented 
in  renal  disorders  like  minimal  change  disease,  focal  segmental  glomerulosclerosis  and 
membranous nephropathy [1]. Adhesion molecules like the integrin α3ß1 and dystroglycan are the 
major  receptors  studied  today,  which  connect  the  podocytes  to  the  glomerular  basement 
membrane (GBM) [2]. During development L1 adhesion molecule is known to be regulated in 
the  renal  epithelium  and  is  involved  in  kidney  branching  morphogenesis  [3].  L1  adhesion 
molecule exists in a transmembrane form, but can also be processed into a soluble form about 
200kDa  by  a  disintegrin and  metalloproteinase  (ADAM10)  [4,  5].  Furthermore,  L1  adhesion 
molecule can be cleaved in vitro in the third fibronectin III domain by trypsin [6], plasmin [7] or 
the proprotein convertase PC5A [8], resulting in a 140kDa and 80 kDa fragment. Interestingly, 
different patterns of proteolytic cleavage of L1 during nephrogenesis have been observed, but the 
significance of this cleavage remains unclear [3]. In addition, a 200 kDa soluble form of L1 
adhesion molecule was found in patients with acute tubular necrosis and may represent a marker 
of distal nephron injury [9]. In the developing rat kidney ADAM10 was highly expressed in the 
late  ureteric  bud  [10].  Recently  we  have  characterized  in  detail  the  tubular  and  glomerular 
ADAM10 expression in the human kidney [11, 12]. Interestingly, we found in renal allograft 
biopsies  with  histopathological  diagnosis  of  acute  interstitial  rejection  increased  tubular 
ADAM10 expression, which was accompanied  by high numbers of infiltrating T-cells [12]. It is 
known, that ADAM10 is involved in the cleavage of growth factors, adhesion molecules and cell 
surface receptors like Notch and their ligands Delta and Jagged [13]. In this context, two recent 
publications have highlighted the importance of the Notch signaling pathway in podocytes for the 
development of glomerular diseases. Waters et al reported, that ectotopic Notch activation in 
developing podocytes leads to glomerulosclerosis [14]. In addition, increased expression of the       
intracellular domain of Notch-1 was found in podocytes of patients with diabetic nephropathy 
and focal segmental glomerulosclerosis [15]. 
To characterize the expression of ADAM10 and its substrates L1 adhesion molecule in more 
detail, we analyzed their expression in a human podocyte cell line and in human renal tissue. We 
demonstrate  that  ADAM10  and  L1  are  expressed  in  human  podocytes.  In  differentiated 
podocytes we detected increased amounts of mature ADAM10 and high levels of soluble L1. In 
addition,  injuring  podocytes  with  puromycin  induced  ADAM10  mediated  cleavage  of  L1. 
Furthermore viable podocytes isolated from urines of patients with glomerular kidney diseases 
expressed constitutively ADAM10. Isolating urinary vesicles from healthy donors and patients 
with  inflammatory  kidney  diseases,  revealed  increased  amounts  of  ADAM10  expression  in 
patients with glomerular kidney diseases. 
 
 Methods 
 
Chemicals 
Interferon-γ (IFN−γ) was purchased from Peprotech (Frankfurt, Germany), hyperfilms and the 
enhanced chemiluminescence (ECL) reagents were ordered from Amersham Pharmacia Biotech 
Europe  GMBH  (Freiburg,  Germany),  all  cell  culture  nutrients  were  from  Invitrogen/Life 
Technologies (Karlsruhe, Germany). The ADAM10 specific inhibitor GI254023X was assayed 
for inhibition of recombinant human ADAM17 and ADAM10 ectodomains as described before 
[16]. 
 
       
Cell Culture 
Human condititionally immortalized podocytes (HPC) were isolated and cultivated as previously 
described  [17].  Prior  to  stimulation,  cells  were  incubated  for  16  h  in  RPMI  1640  medium, 
supplemented with 0.1 mg/ml of fatty acid-free bovine serum albumine. 
 
Experimental subjects 
We examined the urines of a group of 7 individuals composed of 5 patients with glomerular 
diseases (diagnosis of patients are depicted in Table 1) and 2 healthy subjects. 
 
Isolation of cells from human urines 
Freshly  voided  urine  of  healthy  donors  and  patients  with  glomerular  kidney  diseases  were 
centrifuged at room temperature at 700 g for 10 min. The supernatant was removed by careful 
aspiration, the cell pellet was resuspended in 10 ml podocyte medium. The cell suspension was 
placed into culture flasks and incubated at 37°C in 5% CO2.  
 
Antibodies 
Mouse mAb (L1-11A) to the ectodomain of human L1 adhesion molecule and polyclonal L1  
were  provided  from  Prof.  Dr.  Altevogt  (Heidelberg,  Germany).  Monoclonal  antibody  to  the 
extracellular  part  of  ADAM10  was  from  R&D  Systems  (Wiesbaden-Nordenstadt,  Germany). 
Polyclonal anti-ADAM10 antibody from eBioscience (San Diego, USA) was used for Western 
blot and immunofluorescence staining. Polyclonal antibodies against nephrin and podocin were 
kindly provided from Dr. Shuyu Ren (Bern, Switzerland). Monoclonal antibodies for ß1 and α3 
integrin subunits were from Chemicon (Hampshire, United Kingdom, England). WT1 antibody 
for immunofluorescence analysis was purchased from Santa Cruz (Heidelberg, Germany).       
Preparation of supernatants for the detection of soluble molecules 
These assays were described previously [4, 18]. Briefly, cell monolayers in serum-free medium 
were  exposed  to  5 g  or  10 g  puromycin  to  induce  shedding.  The  ADAM10  specific 
metalloproteinase  inhibitor  were  added  15  min  before  treatment.  Cell-free  supernatants  were 
TCA precipitated, protein samples were boiled with non-reducing sodium dodecyl sulfate (SDS) 
sample buffer and investigated by western blot analysis. 
 
Western blot analysis 
Cells were lysed in ice-cold lysis buffer (50mM Tris/HCl,pH 7.4, 150 mM NaCl, 10 % glycerol, 
1% Triton X-100, 2 mM EDTA, 2 mM EGTA, and 1x Complete protease inhibitors, Boehringer 
Complete). Supernatants were TCA precipitated. The membranes were incubated overnight with 
primary antibodies and bound antibodies were detected by anti-rabbit or anti-mouse/horseradish 
peroxidase  conjugates  (Santa  Cruz,  Heidelberg,  Germany)  and  enhanced  chemiluminescence 
system (Amersham, Freiburg, Germany.). 
Cytofluorography 
The  cells  were  stained  with  saturating  amounts  of  mAbs,  either  hybridoma  supernatants  or 
purified  antibodies,  and  phycoerythrin  (PE)-conjugated  goat  antibodies  to  mouse 
immunoglobulins. For intracellular FACS staining, cells were fixed with 1% paraformaldehyd for 
15 min at RT. Cells were washed in PBS and permeabilised with 1% Triton X-100/PBS. Primary 
antibodies were diluted in 1%Triton X-100/PBS and added for 30 min at 4°C to the cells. After 
washing the cells twice with 1%Triton-X-100/PBS, fluorescence coupled secondary antibodies 
were added for 20 min at 4°C in the dark. After extensive washing with 1%TX-100/PBS, stained 
cells were analyzed by a FACScan cell analyzer (Becton & Dickinson, Heidelberg, Germany) 
using Cellquest software (Becton & Dickinson, Heidelberg, Germany).        
Fluorescence microscopy (cells) 
Cells were grown on coverslips and fixed with 4% paraformaldehyde/PBS or with methanol and 
fluorescence staining was carried out as previously described [19]. 
 
Fluorescence microscopy (tissue) 
Paraffin tissue sections were deparaffinized in xylene, rehydrated through a graded ethanol series 
and  washed  in  10mM  phosphate-buffered  150mM  saline,  pH  7.4.  Antigen  retrieval  was 
performed by incubating the tissue sections for 20 min in 0.01M sodium citrate buffer, pH 6.0, in 
a microwave oven (500Watt). After incubation with blocking buffer (0.1% Triton X-100/ PBS 
containing 1% BSA and 10 % horse serum) for 1h, tissue sections were incubated with the first 
antibodies  (diluted  in  1%  BSA/10%  horse  serum  /  PBS  /  0.1%  Triton  X-100)  as  indicated. 
Following washing, bound antibodies were detected by Alexa 488 conjugated goat anti-mouse 
(Molecular Probes, Karlsruhe, Germany) or goat anti-rabbit Cy3 (Molecular Probes, Karlsruhe, 
Germany) secondary antibodies. Nuclei were stained with 4´,6-diamidino-2-phenylindole (DAPI, 
Sigma, Deisenhofen, Germany) and slides were mounted in Fluoromount G (Southern Biotechm, 
Birmingham,  USA).  Evalutation  was  performed  by  fluorescence  microscopy  (Keyence,  Neu-
Isenburg, Germany). 
 
siRNA 
For downregulation of endogenous ADAM10 expression, the following siRNA duplex (MWG 
Biotech AG, Ebersberg, Germany) were used: ADAM10 construct, 5´-AGA CAU UAU GAA 
GGA  UUA  UTT-3´.  As  a  negative  control  an  unspecific  scrambled  siRNA  duplex  (5´-AGG 
UAG UGU AAU CGC CUU GTT-3´) was applied. 
       
Transfection of siRNA  
Twenty-four hours before transfection 5x10
4 cells were seeded in 6-well plates. Transfection of 
siRNA  was  carried  out  using  Oligofectamine  (InVitrogen,  Karlsruhe,  Germany)  and  10nM 
siRNA duplexes (MWG Biotech AG, Ebersberg, Germany) per well. All cells were assayed 48h 
after the transfection.  
 
Reverse transcription–PCR analysis 
RNA from urinary cells was isolated using the RNA Easy Kit according to the manufacturer’s 
protocol (Qiagen, Hilden, Germany). Equal amounts of total cellular RNA (1 µg) were reverse-
transcribed  with  random  primer  by  the  use  of  M-MuLV  Reverse  Transcriptase  (Fermentas, 
St.Leon-Rot, Germany). Transcribed  cDNAs were used  for polymerase chain  reaction (PCR) 
with specific primers for α 3 integrin subunit (5`-CAA GGA TGA CTG TGA GCG G-3´ and 5´-
ATA TAG AGG TTT CCT TGG TCC-3`), β1  integrin subunit (5`-GAG AAG CTC AAG CCA 
GAG G-3` and 5´TCT GTT CAC TTG TGC AAG GG-3`) and podocin (5`-AGA GTA ATT 
ATA TTC CGA CTG G-3´ and 5`-TCA CTG AAT CCA AGG CAA CC-3`). PCR products were 
amplified  using  Taq  DNA  polymerase  (NatuTec,  Frankfurt,  Germany)  and  subjected  to 
electrophoresis using 2% agarose gels followed by ethidium bromide staining. 
 
Isolation of the human glomeruli 
The glomeruli were isolated from the human kidney tissue according to the method of Striker and 
Striker [20] with minor modifications. The cortical tissue was first gently minced with a razor 
blade and then pushed through a steel sieve of 250-µm pore size by using a spatula. The pass-
through was then filtered through  a 150-µm pore size sieve and,  finally, the  glomeruli were 
collected by rinsing with PBS/1%FCS from the surface of a third sieve of 100-µm pore size. The       
preparation  was  examined  under  a  light  microscope  for  purity;  regularly  nearly  100%  pure 
glomeruli were obtained. 
 
Isolation of urinary vesicles 
15 ml of freshly voided urine of healthy volunteers and patients with glomerular kidney diseases 
were used to isolate urinary vesicles with serial centrifugation steps as described previously [19]. 
 
Results 
Surface expression of ADAM10 and L1 is reduced during differentiation of podocytes 
We analyzed the protein expression of ADAM10 and L1 adhesion molecule with FACS-analysis 
in  undifferentiated  and  9  days  differentiated  human  podocytes.  Interestingly,  undifferentiated 
podocytes showed strong ADAM10 and L1 surface expression (Fig. 1A and 1B, green line). In 
contrast, in differentiated podocytes the surface expression of ADAM10 and L1 was significantly 
reduced  (Fig.  1A  and  1B,  red  line).  In  addition,  we  detected  increasing  amounts  of  mature 
ADAM10 in lysates of differentiated  podocytes (Fig. 1C), which correlated with higher amounts 
of soluble L1 (Fig. 1D) and L1-32 (Fig. 1E), the cellular counterpart of soluble L1.  
 
ADAM10 is involved in the cleavage of L1 adhesion molecule  
Podocyte injury occur in many glomerular diseases [21]. To injure podocytes we treated the cells 
with  different  concentrations  of  puromycin.  Interestingly,  increasing  amounts  of  puromycin 
induced  L1-32  in  podocytes  (Fig.  2A),  which  was  accompanied  by  an  increased  amount  of 
soluble L1 (Fig. 2B). In addition with a specific metalloproteinase inhibitor GI254023X (Fig. 2C) 
and ADAM10 specific siRNA (Fig. 2D) we could significantly reduce the release of L1 adhesion 
molecule. Interestingly, the puromycin induced cleavage of L1 was only partially inhibited by       
ADAM10 siRNA, whereas the constitutive release of L1 was almost completely blocked. The 
efficient knockdown of ADAM10 is represented in Fig. 2D. 
 
Urinary cells from nephrotic kidney patients express ADAM10, L1, alpha3 and nephrin 
Viable podocytes are detectable in the urine of patients with glomerular kidney diseases [22]. 
Therefore we isolated urinary podocytes from patients with glomerular diseases. As demonstrated 
by  FACS  analysis  (Fig.3A)  cells  isolated  from  the  urine  of  a  patient  expressed  significant 
amounts of ADAM10 at the cell surface. Interestingly, urinary podocytes expressed mainly the 
mature form of ADAM10 and low levels of full-length L1 (Fig.3B). By RT-PCR (Fig.3C lower 
panel), Westernblot (Fig.3C upper panel) and immunofluorecense (Fig. 3D) of podocyte specific 
marker proteins (integrin α3ß1 or podocin) we confirmed that cells isolated from the urine are 
podocytes. In addition, by intracellular FACS staining using ADAM10 and WT1 as a specific 
marker for podocytes we confirmed that podocytes express ADAM10 (Fig. 3E). To determine if 
L1 is expressed in urinary and glomerular podocytes we performed immunofluorescence and 
westernblot analysis. As shown in Fig.3F urinary podocytes only expressed low levels of L1, but 
L1 expression was induced after the treatment of the cells with proinflammatory cytokine IFN-γ 
(Fig.3F). In addition, L1 expression was also detectable in lysates of glomeruli of normal human 
kidney (Fig. 3G). 
 
Podocytes in human renal tissue express ADAM10  
In glomeruli of human renal tissue we detected ADAM10 expression by immunohistochemistry 
ADAM10 expression (data not shown). To confirm, that podocytes are expressing ADAM10, 
double immunofluorescense analysis with a podocyte specific marker (WT1) was performed. 
ADAM10 expression was detectable in WT1 expressing podocytes (Fig. 4A). In addition, we       
isolated glomeruli out of the human kidney and investigated glomerular lysats by western blot. 
ADAM10 protein expression was detectable in glomeruli lysats (Fig. 4A left lane).  
 
ADAM10 is found in the urine and urinary vesicles of patients with glomerular kidney diseases 
Exosomes in the urine are known to be a rich source for potential biomarkers [23]. Therefore we 
analyzed urine and urinary vesicles isolated from healthy volunteers and patients with glomerular 
diseases for the expression of ADAM10 and L1 adhesion molecule. We detected elevated levels 
of ADAM10 in urine and in urinary vesicles of patients with glomerular diseases compared to 
healthy volunteers (Fig.4B). To investigate if increased amounts of ADAM10 is due to elevated 
levels of urinary vesicles we probed the membranes with CD9 an exosome specific marker. As 
shown in Fig.4B patients with high amounts of vesicular ADAM10, demonstrated lower levels of 
CD9.  Furthermore,  we  detected  only  in  exosomes  of  untreated  and  ionomycin  (induces  the 
release of exosomes) treated human podocytes the mature form of ADAM10, whereas in the 
supernatants of the cells the immature form of ADAM10 could be seen (Fig. 4B). Notably, no 
differences in L1 expression was observed in urine and urinary vesicles of patients compared to 
healthy controls (data not shown). 
 
Discussion 
In this work we demonstrated the expression of ADAM10 and L1 adhesion molecule in human 
podocytes. The importance of ADAM10 and L1 adhesion molecule in developmental processes 
are manifested in knockout models. ADAM10 knockout mice die before embryonic day 10 as a 
result of major defects in epithelial tissues [24]. L1 knockout mice show severe malformation of 
the  nervous  system,  underlyning  the  importance  of  this  molecule  in  the  developing  nervous 
system [25].       
In the kidney it has been suggested, that L1 acts as a guidance molecule in the development of 
distal tubules and collecting ducts [3]. L1 knock out mice develop diverse renal malformations in 
addition  to  neurological  abnormalities  [26].  In  contrast  to  previous  published  data  [27]  we 
detected L1 expression not only in tubular cells but also in immortalized human podocyte cell 
line and in primary podocytes isolated from urine of patients with glomerular disease. In the urine 
of patients with acute tubular necrosis (ATN) high levels of soluble L1 was detectable and the 
authors strongly suggest that urinary L1 could be a potential biomarker of distal injury during 
acute kidney injury (AKI) [9]. Beside urine and serum of patients, exosomes of body fluids may 
provide  an  avenue  for  the  discovery  of  biomarkers  useful  for  the  early  detection  of  kidney 
diseases  and  for  the  monitoring  of  treatment.  We  did  not  find  significant  differences  in  the 
amount of L1 in urine and urinary vesicles of healthy volunteers and patients with glomerular 
kidney diseases (data not shown). In contrast elevated levels of ADAM10 were detectable in 
urine  and  urinary  vesicles  of  patients  with  glomerular  kidney  diseases.  Although  we  have 
analyzed only few urine samples, this finding should be further investigated with higher numbers 
of urine samples from different renal diseases. Interestingly, in the urine of bladder cancer high 
levels of ADAM12 were detectable, suggesting ADAM12 as a promising biomarker for bladder 
cancer [28]. 
Another important substrate of ADAM10 is the Notch receptor which has also a crucial role in 
podocyte development. Interestingly, we found increased amounts of mature ADAM10 during 
differentiation  of  podocytes,  suggesting  ADAM10  as  a  differentiation  marker  for  podocyte 
development.  Importantly,  a  recent  publication  demonstrated  the  involvement  of  the  Notch 
pathway in the development of glomerular disease [15].  In summary our finding that ADAM10 
is expressed in podocytes and found in elevated levels in the urine of patients with glomerular 
diseases  needs  further  investigation  to  clarify  the  involvement  of  this  molecule  in  the       
development of glomerular kidney diseases and its usefulness as a new biomarker for glomerular 
injury. 
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Figure legends 
Fig. 1 
Differentiated podocytes express decreased levels of ADAM10 and L1 adhesion molecule 
protein on the cell surface 
Flow  cytometry  histograms  represents  number  of  podocytes  (cell  counts,  y  axis)  and  the 
fluorescence intensity (x axis) of ADAM10 (A) and L1 adhesion molecule (B) and the isotype-
matched  control  IgG  antibody  (filled  peak)  in  undifferentiated  (green  peak)  and  9  days 
differentiated  cells  (red  peak).(C)Western  Blot  analysis  from  lysates  of  undifferentiated 
podocytes  (HPC  undiff.),  4  days  differentiated  podocytes  (HPC  4  d  diff.)  and  9  days 
differentiated  podocytes  ((HPC  9  d  diff.)  with  an  ADAM10  specific  antibody.  Blots  were 
stripped and re-probed with an antibody specific for ß- actin as a loading control. 
(D)  Western  blot  analysis  of  the  supernatants  of  undifferentiated    (HPC  undiff.)  and  9  days 
differentiated podocytes (HPC 9 d diff.) with L1-11A, an antibody specific for the ectodomain of 
L1  adhesion  molecule.  (E)  Cell  lysates  were  analyzed  by  western  blot  technique  with  a  L1 
specific antibody (pcyt). ß-actin western blot was used as a loading control. 
 
Fig. 2  
Puromycin treated podocytes show increased levels of L1-32 and soluble L1 
(A) Human podocytes were treated for 24 h with 5 g/ml and 10 g/ml puromycin. Cells were 
lysed and western blot experiments were done with an antibody against the cytoplasmic tail of 
L1.  
(B) Human podocytes were treated for 6 h and 24 h with 5 g/ml and 10  g/ml puromycin (Puro), 
supernatants were collected and after TCA-precipitation, equal amounts of protein samples were 
loaded  on  a  SDS-PAGE.  Membranes  were  probed  with  L1-11A,  an  antibody  against  the       
ectodomain of L1. 
(C) Human podocytes were pretreated 30 min with 3 M ADAM10 inhibitor GI254023X (GI) 
before incubating cells for 6 hours with 10  g/ml puromycin (Puro). Supernatants were analyzed 
for soluble L1 by western blot analysis. 
(D) Western Blot analysis of soluble L1 after the transfection of ADAM10 specific siRNA in the 
presence or absence of 5  g/ml puromycin (24 hour treatment). As a negative control a scrambled 
siRNA was used (A10 = ADAM10, sc = Scrambled, Puro = Puromycin) 
Efficient  knockdown  of  ADAM10  was  controlled  by  westernblot  with  ADAM10  specific 
antibody (A10 = ADAM10 , sc = scrambled) and equal loading of the samples were determined 
by β-actin westernblot. 
 
Fig. 3 
Podocytes isolated out of the urine of patients with nephrotic syndrome express ADAM10  
Cells  isolated  out  of  the  urine  of  a  patient  with nephrotic  syndrome  were  analyzed  by  flow 
cytometry  (A+E),  Western  blot  (B+C),RT-PCR  (C  lower  panel),  and  immunofluorescence 
(D+F). 
(A) Cells isolated from the urine  were stained with ADAM10 or  L1  adhesion molecule and 
analyzed with Cellquest software from Becton Dickinson ( Heidelberg, Germany). 
(B) Urinary cells were lysed and western blots (WB) with ADAM10 and L1 (L1 11A) specific 
antibodies were performed. 
(C) Lower panel: RT-PCR with α3, β1, and podocin specific primers on cDNA of cells isolated 
from the urine. Upper panel: Western blot analysis with α3, β1 and podocin specific antibodies in 
lysats of cells isolated from the urine.       
(D) Immunofluorescence double staining of cells isolated from the urine with podocyte specific 
marker proteins α3, nephrin, β1 and podocyin antibodies. Images were documented with a Zeiss 
camera. 
(E) Urinary cells were investigated by intracellular FACS staining using WT1 (podocyte specific 
marker protein) and ADAM10 antibodies. Stained cells were analyzed with Cellquest software 
from Becton Dickinson ( Heidelberg, Germany). 
(F) Immunofluorescence staining of untreated (control) and IFN-γ treated urinary podocytes with 
L1 specific primary antibodies followed by Alexa 488 coupled secondary antibodies. Nuclei of 
urinary podocytes were stained and visualized with DAPI. Images were documented with a Zeiss 
camera. 
(G) Glomeruli from human kidney were isolated and glomerular lysats were prepared, proteins 
were loaded on a SDS gel and western blot analysis were performed using a polyclonal antibody 
against the cytoplasmic tail of L1. 
 
Fig.4 
ADAM10 is expressed in podocytes in human renal tissue 
(A) Glomeruli from human kidney were isolated and lysed and investigated by an ADAM10 
specific  westernblot  (left  panel).  Right  panel,  double  immunofluorescence  analysis  on  a 
human  kidney  section  with  WT1  (red)  and  ADAM10  (green)  antibodies,  demonstrating 
ADAM10 expression in WT1 positive podocytes. 
(B) Increased ADAM10 levels are found in the urine of patients with glomerular kidney 
diseases 
Western Blot analysis of ADAM10 expression in urine and urinary vesicles of healthy volunteers 
(HV  1-2)  and  patients  with  glomerular  kidney  diseases  (number  of  patients  P1-5,  ADAM10       
expression in supernatants (SN) and vesicles (VES) from untreated (HPC C) or treated with 1 M 
ionomycin  (HPC  IONO)  for  24  h.  Membranes  were  reprobed  with  CD9  an  specific  marker 
protein of exosomes. 
 
 
Table  1:  Clinicopathological  data  of  patients  which  were  analyzed  for  urinary  ADAM10 
expression (S-crea= serum creatinin, m=male, f= female). 
 
Patients  Diagnosis  Age  Sex  Protenuria (g/day)  S-crea 
P-1  Lupus nephritis  46  f  6,314  1,32 
P-2  Morbus Wegener 
(not active) 
72  f  0,113  0,81 
P-3  IgA nephritis  72  m  3,435  5,86 
P-4  IgA nephritis  38  m  1,143  4,35 
P-5  Lupus nephritis  38  f  3,969  2,01 
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